

Novocure Ltd  
Form 8-K  
July 28, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d)**

**of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 28, 2016**

**NovoCure Limited**

**(Exact name of registrant as specified in its charter)**

**Jersey**  
**(State or Other Jurisdiction of**  
**Incorporation or Organization)**

**001-37565**  
**(Commission**  
**File Number)**  
**Le Masurier House**

**98-1057807**  
**(IRS Employer**  
**Identification No.)**

Edgar Filing: Novocure Ltd - Form 8-K

**La Rue Le Masurier**

**St. Helier, Jersey JE2 4YE**

**(Address of Principal Executive Offices)**

**Registrant's telephone number, including area code: +44 (0)15 3475 6700**

**N/A**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. to Form 8-K):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.02. Results of Operations and Financial Condition**

On July 28, 2016, the Company issued a press release announcing certain financial results for the quarter ended June 30, 2016. A copy of the press release is attached as Exhibit 99.1.

The information contained in this Current Report shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act ), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.**

*(d) Exhibits*

Exhibit No.	Description
99.1	Press Release, dated July 28, 2016

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**NovoCure Limited**

(Registrant)

Date: July 28, 2016

By: /s/ Wilhelmus Groenhuysen

Name: Wilhelmus Groenhuysen

Title: Chief Financial Officer

**Index to Exhibits**

Exhibit No.	Description
99.1	Press Release, dated July 28, 2016